Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada. Show more

Location: #140, 14315 – 118 Avenue, Edmonton, AB, T5L 4S6, Canada | Website: https://www.auriniapharma.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

1.134B

52 Wk Range

$5.20 - $10.67

Previous Close

$8.39

Open

$8.35

Volume

1,497,543

Day Range

$8.32 - $9.10

Enterprise Value

909.7M

Cash

312.6M

Avg Qtr Burn

N/A

Insider Ownership

9.07%

Institutional Own.

47.22%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Lupkynis (Voclosporin) Details Lupus nephritis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AUR200 Details Autoimmune disease	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Voclosporin Details Focal segmental glomerulosclerosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Voclosporin Ophthalmic Solution Details Dry eye syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.